December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.13 -0.24 (-0.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
40 41 Next >
News headline image
US Stock Futures Lower Following Friday's Rally; Tesla In Focus ↗
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording sharp gains in the previous session. The Dow Jones jumped by around 750 points on Friday. All the... 
Via Benzinga
News headline image
New Drugs Approvals Bring No Relief for Ailing Innovent Bio ↗
Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its... 
Via Benzinga
News headline image
2 High-Yielding Dividend Stocks That Haven't Been This Cheap in Years ↗
Is now the time to buy Sanofi and Intel? 
Via The Motley Fool
News headline image
3 Red-Hot Stocks That Could Continue to Beat the Market ↗
Investors are betting on these companies' revenue growth prospects. 
Via The Motley Fool
News headline image
Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product ↗
 
Via Benzinga
News headline image
Sanofi In-Licenses Preclinical Genetic Disease Candidate From An Unknown Biotech ↗
 
Via Benzinga
News headline image
Sanofi's Rare Disease Drug Xenpozyme Scores FDA Approval ↗
 
Via Benzinga
News headline image
Sanofi's Hemophilia Candidate Goes Under Priority FDA Review ↗
 
Via Benzinga
News headline image
2 Top Healthcare Stocks to Buy Right Now ↗
Healthcare is about as sticky of a business model as you'll find. 
Via The Motley Fool
News headline image
7 Under-$50 Stocks to Buy to Tap Into a Hidden Bull Market ↗
Those seeking compelling market ideas during this storm may want to consider these relevant under-$50 stocks to buy. 
Via InvestorPlace
News headline image
2 Stocks Jumping in Thursday's Premarket Trading ↗
Get an early start on the events of the day. 
Via The Motley Fool
News headline image
Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate ↗
 
Via Benzinga
News headline image
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis ↗
 
Via Benzinga
News headline image
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test ↗
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
News headline image
TG Therapeutics Touts Encouraging Data From Multiple Sclerosis Candidate ↗
 
Via Benzinga
News headline image
NASDAQ:SNY Investor Alert: Investigation over Potential Wrongdoing at Sanofi ↗
San Diego, CA -- (SBWIRE) -- 09/20/2022 -- An investigation on behalf of investors in shares of Sanofi (NASDAQ:SNY) was announced over potential breaches of fiduciary duties by certain directors at... 
Via SBWire
News headline image
Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer ↗
 
Via Benzinga
News headline image
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger ↗
 
Via Benzinga
News headline image
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing ↗
 
Via Benzinga
News headline image
ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients ↗
 
Via Benzinga
News headline image
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease ↗
 
Via Benzinga
News headline image
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report ↗
 
Via Benzinga
News headline image
Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids ↗
 
Via Benzinga
News headline image
Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash... ↗
Wall Street Journal 
Via Benzinga
News headline image
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
News headline image
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 63 companies set new 52-week lows. 
Via Benzinga
News headline image
Upstart Digital Health Company, DarioHealth, Announces Significant Contract with National Health Plan Provider, Giving Millions Access to Mental Health Resources ↗
DarioHealth Corp. (NASDAQ: DRIO) recently announced 
Via Benzinga
News headline image
MarketBeat: Week in Review 8/15 - 8/19
The economic reports continue to signal volatility. You can count on MarketBeat analysts to bring you the stocks and stories that are driving the market. 
Via MarketBeat
Topics Economy Workforce
News headline image
Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions. 
Via MarketBeat
Topics Intellectual Property
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.